180 Wealth Advisors LLC Sells 383 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

180 Wealth Advisors LLC cut its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 4.8% during the first quarter, HoldingsChannel.com reports. The firm owned 7,654 shares of the medical device company’s stock after selling 383 shares during the period. 180 Wealth Advisors LLC’s holdings in Tandem Diabetes Care were worth $271,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of TNDM. Vanguard Group Inc. boosted its stake in Tandem Diabetes Care by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock valued at $207,708,000 after buying an additional 18,571 shares in the last quarter. Eminence Capital LP boosted its stake in Tandem Diabetes Care by 76.1% in the 3rd quarter. Eminence Capital LP now owns 5,490,017 shares of the medical device company’s stock valued at $114,028,000 after buying an additional 2,372,458 shares in the last quarter. Jennison Associates LLC boosted its stake in Tandem Diabetes Care by 14.9% in the 4th quarter. Jennison Associates LLC now owns 1,290,590 shares of the medical device company’s stock valued at $38,176,000 after buying an additional 167,675 shares in the last quarter. GW&K Investment Management LLC acquired a new stake in Tandem Diabetes Care in the 4th quarter valued at $36,288,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Tandem Diabetes Care by 0.3% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 793,488 shares of the medical device company’s stock valued at $16,481,000 after buying an additional 2,633 shares in the last quarter.

Insider Transactions at Tandem Diabetes Care

In other news, Director Dick Allen sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $51.68, for a total value of $258,400.00. Following the completion of the sale, the director now directly owns 24,396 shares of the company’s stock, valued at $1,260,785.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 2.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently commented on TNDM shares. SVB Leerink raised Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $34.00 to $45.00 in a research note on Thursday, April 25th. Piper Sandler reissued an “overweight” rating and issued a $50.00 price objective (up previously from $35.00) on shares of Tandem Diabetes Care in a research note on Friday, May 3rd. Oppenheimer boosted their price objective on Tandem Diabetes Care from $47.00 to $58.00 and gave the stock an “outperform” rating in a research note on Monday, June 10th. Barclays boosted their price objective on Tandem Diabetes Care from $39.00 to $55.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. Finally, Citigroup raised Tandem Diabetes Care from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $40.00 to $57.00 in a research note on Wednesday, May 22nd. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and an average price target of $51.25.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $40.29 on Friday. The stock’s fifty day simple moving average is $44.52 and its 200-day simple moving average is $33.84. The company has a quick ratio of 3.01, a current ratio of 3.81 and a debt-to-equity ratio of 1.43. Tandem Diabetes Care, Inc. has a 12-month low of $13.82 and a 12-month high of $53.69.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Thursday, May 2nd. The medical device company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.17. The business had revenue of $191.67 million during the quarter, compared to the consensus estimate of $173.06 million. Tandem Diabetes Care had a negative return on equity of 34.38% and a negative net margin of 18.37%. Research analysts predict that Tandem Diabetes Care, Inc. will post -1.71 earnings per share for the current fiscal year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.